Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children — HIT-REZ-2005

Ependymomas Clinical Trial

Official title:
Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents

Status Completed

Clinical Trial Summary

The purpose of this study is to improve overall survival while maintaining a good quality of life in pediatric patients with refractory or recurrent brain tumors (medulloblastomas, supratentorial PNETs, ependymomas WHO grade II and III). Response to different chemotherapy options (intravenous versus oral chemotherapy, intraventricular chemotherapy) as part of a multimodal therapy will be assessed. Progression-free, overall survival and toxicity will be evaluated additionally.

Clinical Trial Description

Parts of the study:

P-HIT-REZ-2005: a trial for the treatment of relapsed PNETs (medulloblastomas,supratentorial PNETs)

E-HIT-REZ-2005: a trial for the treatment of relapsed ependymomas (Phase II-Study with temozolomide)

Phase II-Study: intraventricular therapy with etoposide in neoplastic meningitis in relapsed PNETs and ependymomas with subarachnoid tumor manifestation (window study) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00749723
Study type	Interventional
Source	University Hospital, Bonn
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	February 1, 2006
Completion date	January 31, 2016

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01251913` - A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes
Active, not recruiting	`NCT00517959` - SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors	Phase 3
Terminated	`NCT03727841` - Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma	Phase 2